The use of lipid-protamine-DNA (LPD) nanoparticles loaded with PD-L1 plasmid (to inhibit PD-L1 signaling) in addition to oxaliplatin (to induce immune response) in mice has been shown to work synergistically to inhibit tumor growth, reduce toxicity, and may cause the tumor to be more immunogenic, leading to better response to PD-L1 therapy [130]. The gene discussed is CD274; the disease is neoplasm.